Wolverine Asset Management’s Cytokinetics CYTK Stock Holding History

Wolverine Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,000	Closed	-$318K	–	1751
2025 Q4	$318K	Hold	5,000	–	–	﹤0.01%	1034
2025 Q3	$275K	Hold	5,000	–	–	﹤0.01%	963
2025 Q2	$165K	Hold	5,000	–	–	﹤0.01%	1053
2025 Q1	$201K	Hold	5,000	–	–	﹤0.01%	1006
2024 Q4	$235K	Sell	5,000 -4,400	-47%	-$229K	﹤0.01%	1000
2024 Q3	$496K	Hold	9,400	–	–	0.01%	864
2024 Q2	$509K	Sell	9,400 -17,100	-65%	-$1.03M	0.01%	836
2024 Q1	$1.86M	Sell	26,500 -48,200	-65%	-$3.73M	0.02%	512
2023 Q4	$6.24M	Buy	74,700 +18,700	+33%	+$677K	0.05%	307
2023 Q3	$1.65M	Hold	56,000	–	–	0.02%	585
2023 Q2	$1.83M	Buy	56,000 +18,900	+51%	+$699K	0.02%	529
2023 Q1	$1.31M	Sell	37,100 -40,700	-52%	-$1.66M	0.02%	619
2022 Q4	$3.56M	Buy	77,800 +51,700	+198%	+$2.22M	0.04%	425
2022 Q3	$1.26M	Buy	+26,100	New	+$1.26M	0.01%	708

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wolverine Asset Management's CYTK Position: Q1 2026 in Review

Wolverine Asset Management reduced its Cytokinetics (CYTK) stake by 98% in Q1 2026, selling an estimated $342K and leaving 120 shares worth $7.91K. The position accounts for ﹤0.01% of the portfolio, ranked #1446.

Wolverine Asset Management first reported a position in CYTK in Q4 2025 and has held it in 2 quarters since. The position peaked at $349K in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Wolverine Asset Management held 120 shares of Cytokinetics worth $7.91K as of Q1 2026.
Wolverine Asset Management sold 5,380 Cytokinetics shares in Q1 2026, an estimated $342K.
Cytokinetics made up ﹤0.01% of Wolverine Asset Management's portfolio in Q1 2026, its #1446 holding.
Wolverine Asset Management first reported a position in Cytokinetics in Q4 2025 and has held it in 2 quarters since.
Wolverine Asset Management's Cytokinetics position peaked at $349K in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.